As Vice President of Assay Development, Aravind leads the group responsible for developing point-of-care devices that is optimized for performance and manufacturability. He brings over 15 years of experience in developing point-of-care diagnostics spanning markers in cardiac, endocrine and men's health applications.
During his graduate work with Prof. Jon Dordick at Rensselaer, Aravind used microfluidic biochips to explore the flexibility of polyketide synthase pathways. Aravind's post-doctoral research at MIT included innovative glycan-array based approaches for monitoring influenza transmission that was out-licensed to Visterra Inc (currently a subsidiary of Otsuka Pharmaceuticals). Subsequently, at Instrumentation Laboratories and at OPKO Health, Aravind served in multiple roles with increasing responsibilities. Most recently, at OPKO, he was key to completing assay development and verification activities for the Sangia Total PSA Test (FDA PMA approved in 2019) and oversaw menu expansion on the platform.
Aravind received his Phd in Chemical and Biological Engineering from Rensselaer Polytechnic Institute and completed his post-doctoral training at MIT.
Vice President, Assay Development